The

present mini-review attempts to elucidate the possible relationship between NO and DOMS, based upon current literature. (c) 2011 Elsevier Inc. All rights reserved.”
“Objective: The roles of perioperative hyperglycemia and diabetes in the risk stratification of patients undergoing coronary artery bypass graft surgery are unclear. The aim of this study is to explore the influence of perioperative hyperglycemia on postoperative mortality.

Method: A prospective, observational study of 5050 patients undergoing cardiopulmonary bypass for coronary artery bypass graft surgery at 70 international centers was conducted, with 7500 measured variables per patient and outcomes adjudicated centrally. Postoperative blood glucose levels measured from the day of surgery to postoperative Nutlin-3 supplier day 3 were available for 4799 patients. Multivariable logistic regression was Romidepsin concentration used to determine the association of hyperglycemia

with hospital mortality.

Results: A total of 164 patients died during hospitalization (3.2%). Mortality was significantly higher in the diabetic population compared with the nondiabetic population (4.2% vs 2.9%; P = .02). In nondiabetic patients, maximum postoperative blood glucose between 250 and 300 mg/dL (adjusted odds ratio, 2.56; 95% confidence interval, 1.18-5.57; P = .02) and maximum blood glucose of 300 mg/dL or greater (adjusted odds ratio, 2.74; 95% confidence interval, 1.22-6.16; P = .01), compared with maximum blood glucose less than 200 mg/dL, and postoperative insulin A769662 treatment (adjusted odds ratio, 2.04; 95% confidence interval, 1.12-3.70), were independent

risk factors for an increased risk of in-hospital mortality. In diabetic patients, hyperglycemia was not associated with a higher mortality risk.

Conclusions: Postoperative hyperglycemia is associated with increased in-hospital mortality in nondiabetic patients after coronary artery bypass graft surgery. In diabetic patients, hyperglycemia was not associated with mortality. (J Thorac Cardiovasc Surg 2011; 142: 430-7)”
“The name phenoxazinone synthase (PHS, 2-aminophenol:oxygen oxidoreductase, EC 1.10.3.4) is used for the enzyme catalysing the oxidative coupling of substituted o-aminophenols to produce phenoxazinones. This review reveals that the traditional classification of PHS conflicts with recent sequence-based information that shows its relationship with two distinct copper protein groups. Different PHS roles, namely spore pigmentation in Streptomyces antibioticus (phsA) and biosynthesis of the antibiotic grixazone in Streptomyces griseus subsp. griseus (GriF), indicate an example of convergent evolution. Here, we review the classification, distribution and roles of PHSs, comparing them with copper oxidases at genetic and structural levels and exploring their potential application in the production of new antibiotics.